Company
Melbourne, VIC
Every investor coverage indicates participated in a round Paradigm Biopharmaceuticals raised.
Companies Paradigm Biopharmaceuticals acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Justin Cahill | CFO (former) | @AuManufacturing |
Stories naming Paradigm Biopharmaceuticals. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Paradigm Biopharmaceuticals appointed FTI Consulting administrators after its Phase 3 trial failed an interim efficacy threshold, and now seeks to restructure debts via a deed of company arrangement.
Biotech Paradigm Biopharmaceuticals appoints rheumatology specialist Daniel Furtner as chief medical officer; predecessor Donna Skerrett stays as senior scientific advisor, and the firm's late-stage osteoarthritis trial has finished enrolling 538 participants.
Briefs roundup: Starpharma names a new CFO, Weld Australia urges trades diversity, the Economic Accelerator bill passes, H2X Global enters AWS's clean energy accelerator, and A.H. Beard partners with the Sleep Health Foundation.
Techboard's September 2022 roundup reports Australian raises led by Morse Micro's $140m Series B, several acquisitions including ResApp Health to Pfizer, fund closes by Telstra Ventures, OIF and Main Sequence, and open raises.
Techboard's monthly roundup tallies August 2022 private funding at $207m across 22 deals, listing the month's raises, BlackRock's acquisition of Akaysha Energy, One Click Life's reverse takeover listing, and several fund closes.
Also Startup Daily